Program

Event format

The symposium will be hybrid and bilingual with simultaneous translation, so you can follow all the information without loss.

Friday, 08.12.2023

Saturday, 09.12.2023

Friday, 08.12.2023

Saturday, 09.12.2023

Cookie Consent Banner von Real Cookie Banner

9.00	Welcome	Axel Heidenreich, Köln, DE

9.10	Prostate Cancer 1
	Early detection and management of organ confined prostate cancer	Axel Heidenreich, Cologne, GER; Jörn Witt, Düsseldorf, GER
9.10	concepts of individual early detection	Jan Radtke, Düsseldorf, DE
9.22	which imaging modality is best for early detection?	Aantti Rannikko, Helsinki, FIN
9.34	10 debunked myths about prostate cancer	Scott Eggener, Chicago, USA
9.46	Discussion

9.56	Organ confined prostate cancer
10.05	Still too much surgery for low risk disease	Axel Heidenreich, Köln, DE
10.15	Aktive Surveillance: Integration of WHO group 2	Scott Eggener, Chicago, US
10.30	Pro and Contra
10.30	Case Pesentation: Christina Steinbach, Cologne, GER
10.32	HIFU-Hemiablation is treatment of choice	Daniel Eberli, Zürich, SUI
10.41	radical prostatectomy remains No 1	Jeff Karnes, Rochester, US

10.50	Discussion

11.00	Satellite Symposium 1 \| AstraZeneca GmbH

11.45	Coffee Break

12.30	non muscle invasive bladder cancer	Maximilian Burger, Regensburg, GER; Florian Roghmann, Herne, GER

12.30	new risk classification of intermediate risk bladder cancer	Mauricio Brausi, Modena, IT
12.42	Do we really need fluorescence cystoscopy?	Martin Kriegmair, München, DE
12.54	Pro and Contra: management of CG-refraktory bladder cancer
	Case Presentation: NMBC – BCG-Versager – Zystektomie oder ausnutzen andere Therapieoptionen	Jakob Musil, Magdeburg, DE
12.56	Pro radical cystectomy	Mauricio Brausi, Modena, I
13.06	Pro new intravesical and systemic treatment options	Florian Roghmann, Herne, DE

13.16	Discussion

13.21	Muskel invasive bladder cancer
13.21	Role of microbiom for response to systemic chemotherapy	Pia Paffenholz, Köln, DE

13.36	Pro and Contra: TURB is superfluous!!
13.36	TURB remains Standard	Maximilian Burger, Regensburg, DE
13.46	mpMRT is safe enough	Jürgen Fütterer, Nijmegen, NL

13.55	Discussion

14.05	SEMI-LIVE Surgery: New surgical methods for urothelial cancer
14.05	En-Bloc cystectomy and Lymphadenectomy	Eirik Kjobli, Trondheim, NOR
14.15	prostate sparing radical cystectomy	David Pfister, A. Heidenreich, Köln, DE
14.25	Ileocoecal-Pouches with umbilical stoma	N.N.
	Organ sparing approach for UUTUC	Uwe-Bernd Liehr, Magdeburg, DE

14.35	Discussion
14.45	„Why the Y? Human genetics as key for differences in uro-oncology	Martin Zenker, Magdeburg, DE


15.25	Satellite Symposium 2 \| Novartis Radiopharmaceuticals GmbH

16.10	Prostate cancer 2: locally advanced prostate cancerModeration
	Pro and Contra: pLAD is superfluous
16.10	Case Presentation: Constantin Rieger, Cologne, GER
16.12	Pro PSMA	Christian Gratzke, Freiburg, DE
16.22	Contra and Pro epLAND	Jeff Karnes, Rochester, USA
16.32	pN1: what to do?	Isabel Heidegger, Innsbruck, AU

16.47	Pro and Contra: ligometastatic HSPC with bone metastases
	Case Presentation: mHSPC – Oligometastasierung – bestrahlen oder systemische Therapie	Florian Wallstab, Magdeburg, DE
16.49	SBRT is the way to go	Alexander Papachristofilou, Basel, SUI
16.59	ADT (±RT) remains the best option	Gunhild von Amsberg, Hamburg, DE

17.09	Discussion

17.20	prostate cancer 3: metastatic HSPC and CRPC	Isabel Heidegger, Innsbruck, AU; David Pfister, Cologne, GER

17.20	role of bicalutamide and intermittent ADT 2023	Martin Schostak, Magdeburg, DE
17.32	Molecular Analysis: who, when and which panel?	Anders Bjartell, Lund, SE
17.44	177Lu-PSMA Therapy: when and who?	Ken Herrmann, Essen, DE
17.56	current algorithm of sequential therapy	Aurelius Omlin, Zürich, SUI
18.08	Discussion

18.15	End of day 1

8.30	Welcome	Axel Heidenreich, Köln, DE

8.35	urothelial carcinoma of the upper urinary tract	Oliver Hakenberg, Rostock, GER; Friedemann Zengerling, Ulm, GER

	Locally advanced urothelial carcinoma of the renal pelvis
	Case presentation: Felix Seelemeyer, Cologne, GER
8.35	role of systemic therapy	Anja Lorch, Zürich, SUI

	Pro and Contra: distal ureteral tumor – what to do?
8.47	Case presentation: UTUC – Harnleitertumor – Organerhalt vs. NUX	Johanna Vogt, Magdeburg, DE
8.49	radical nephroureterectomy and Lymphadenectomy	Vsevolod Matveev, Moskau, RUS
8.56	kidney preserving surgery	Joyce Baard, Amsterdam, NL

9.03	Discussion

9.13	Renal Cell Carcinoma	Axel Heidenreich, Cologne, GER; Jens Bedke, Stuttgart, GER

9.13	State-of -the ART: contrast enhanced CT despite renal insufficiency
		Thomas Benzing, Köln, DE
9.28	focal brachytherapy in the management of renal cancer	Maciej Pech, Magdeburg, DE

	Pro cnd Contra: organ sparing surgery is the standard approach for cT2 RCC
9.43	Case presentation: Theresa von Zehmen, Cologne, GER
9.45	Pro	David Pfister, Köln, DE
9.52	Contra	Friedemann Zengerling, Ulm, DE

10.00	Discussion

10.10	Satellite Symposium 3 \| MSD SHARP & DOHME GmbH

10.55	Coffee Break

11.25	locally advanced renal cell carcinoma	Pia Paffenholz, Cologne, GER; Martin Schostak, Magdeburg, GER
11.25	is locoregional lymphadenectomy the new standard at radical nephrectomy prior to adjuvant immunoncological therapy?	Angelika Borkowetz, Dresden, DE
11.37	residual tumor resection following immune oncological treatment	Jens Bedke, Stuttgart, DE


11.49	Discussion

12.00	Testis Cancer/penile cancer
12.00	organ sparing surgery of penile cancer: surgical technique and results	Oliver Hakenberg, Rostock, DE
12.15	Is there a benefit of secondary opinion centres?	Mark Schrader, Berlin, DE
12.27	Treatment options of clinical stage IIA/B NSGCT	Axel Heidenreich, Köln, DE

12.39	Discussion

12.50	Satellite Symposium 4 \| Astellas Pharma GmbH

13.35	Adjourn and outlook for 2025	Martin Schostak